Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Digene to sell HPV (Human Papilloma Virus) test in Japan:

This article was originally published in Clinica

Executive Summary

Digene has received clearance in Japan to market its Hybrid Capture 2 HPV test for the detection of human papillomavirus, as a follow-up test to border line Pap smear results. The Gaithersburg, Maryland-based firm has also recently filed for US FDA approval to use the HPV DNA test in conjunction with the Pap smear as a primary screen for cervical cancer and its precursors in women age 30 and over.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065668

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel